GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a ...

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK GSK stock has risen 18.6% in the past three months. The price recovery was backed by strong third-quarter results, wherein the British drugmaker beat estimates for both earnings and sales. The ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

GSK (GSK) shares clocked seven straight sessions of gains, as the stock rose 1.7% at $60.19 on Friday. The multinational healthcare giant gained 16.8% in the preceding six sessions. The stock has ...

GSK stock rose 0.4% after Berenberg upgraded to buy with a £22 target and GSK announced a $750M deal with Chimagen Biosciences for a multiple myeloma asset.

With its consensus-beating Q2 2026 results on Tuesday, GSK (GSK) announced a three-year program to reduce annual expenditure by £1.9B ($2.5B) in a bid to fund investment in its late-stage pipeline and ...

GSK GSK shares have lost 13.8% in six months despite solid underlying operating performance. Although second-quarter core sales rose 5%, core operating profit increased 7% and 2026 guidance was ...

At the close on September 14, 2026, GSK stock gained 4.63% in London to 1,854.5 pence, outperforming the FTSE 100 as positive lung cancer trial data drove a session range between roughly 1,770 and ...

The revised score means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. The market's biggest winners often have a 95 or higher rating in ...